Best GLP-1 Medications in New York: 2026 Guide

Last updated: April 2026

More than 42% of adults in the United States live with obesity, and New York is no exception — roughly 1 in 4 New York City adults has obesity according to the NYC Department of Health's 2024 Community Health Survey. GLP-1 receptor agonists have become the most significant pharmaceutical development in weight management in decades. But if you're a New Yorker trying to figure out which medication is right for you, the landscape can feel overwhelming. Different drugs, different doses, different price tags. Insurance that covers one but not another. Clinics on every corner promising results.

This guide cuts through the noise. We break down every GLP-1 medication available in New York in 2026, compare real-world pricing, explain your insurance options, and help you make a decision that actually fits your life.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs that must be prescribed and monitored by a licensed healthcare provider. Always consult your doctor before starting, stopping, or changing any medication. Individual results vary, and these medications carry risks and side effects that should be discussed with your physician.

Affiliate Disclosure: The GLP-1 Daily may earn a commission from products and services linked in this article. This does not affect our editorial recommendations or the price you pay.

What Are GLP-1 Medications and Why Are They So Popular in New York?

GLP-1 receptor agonists mimic a natural hormone called glucagon-like peptide-1. Your gut releases this hormone after you eat. It tells your brain you're full, slows stomach emptying, and helps regulate blood sugar. The pharmaceutical versions amplify these effects dramatically.

The result? Patients lose 15-25% of their body weight on average, depending on the specific medication. That's not a typo. For a 250-pound person, that could mean losing 37 to 62 pounds. Clinical trials for tirzepatide (the active ingredient in Mounjaro and Zepbound) showed participants losing up to 22.5% of body weight over 72 weeks in the SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022).

New York has become ground zero for GLP-1 adoption for several reasons. The city has a dense network of endocrinologists, obesity medicine specialists, and telehealth platforms. New York State's insurance regulations tend to be more favorable for weight management coverage than many other states. And the culture here — fast-paced, health-conscious, willing to try new approaches — has made New Yorkers early adopters.

The numbers tell the story. Prescriptions for GLP-1 medications in New York State grew by an estimated 58% between 2023 and 2025, according to IQVIA prescription tracking data. Nationwide, the GLP-1 market hit $50 billion in U.S. sales in 2025, with projections from Morgan Stanley suggesting it could reach $105 billion by 2030. New York metro area prescriptions account for roughly 8% of the national total — disproportionate to the state's 6% share of the U.S. population.

But popularity doesn't mean simplicity. There are now more than half a dozen GLP-1 options on the market, each with different mechanisms, dosing schedules, delivery methods, and price points. Choosing the right one depends on your health profile, your insurance, and your goals.

Dr. Louis Aronne, Director of the Comprehensive Weight Control Center at Weill Cornell Medicine in New York City, put it this way: "We're no longer asking whether GLP-1 medications work — we know they do. The question in 2026 is which medication, at which dose, through which delivery method, gives each individual patient the best outcome with the fewest side effects."

That's exactly what this guide helps you answer.

Which GLP-1 Medications Are Available in New York in 2026?

Here's the full lineup of GLP-1 and GLP-1-based medications currently available to New York patients, along with their key characteristics.

Semaglutide Injectables: Ozempic and Wegovy

Ozempic (semaglutide 0.25mg to 2mg) is FDA-approved for type 2 diabetes but is widely prescribed off-label for weight loss. Wegovy (semaglutide 0.25mg to 2.4mg) uses the same active ingredient at a higher maximum dose and carries an FDA approval specifically for chronic weight management.

Both are once-weekly injections. Wegovy's STEP 1 clinical trial showed an average weight loss of 14.9% over 68 weeks. The SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major adverse cardiovascular events — a finding that expanded insurance coverage significantly.

Cash-pay pricing in 2026: approximately $349/month for maintenance doses of both Ozempic and Wegovy. Introductory offers from Novo Nordisk bring some patients in at $199/month for the first two months.

Oral Wegovy (Semaglutide Pill)

The FDA approved oral Wegovy on December 22, 2025, and it became available in early 2026. This was a watershed moment. Same active ingredient as the injections, similar efficacy in clinical trials, but no needles required.

The oral formulation starts at $149/month for lower doses through Novo Nordisk's direct pricing program. This price was part of a commitment Novo Nordisk made to the federal government. For patients who've been hesitant about self-injection — and there are many — this changes the calculus entirely. Read more in our coverage of the FDA approval of the new oral GLP-1 medication.

Tirzepatide: Mounjaro and Zepbound

Mounjaro (tirzepatide) is approved for type 2 diabetes. Zepbound (tirzepatide) is its weight-loss-specific sibling. Both are once-weekly injections from Eli Lilly.

Tirzepatide is a dual GIP/GLP-1 receptor agonist — it hits two hunger-regulating pathways instead of one. The clinical data reflects this dual mechanism. SURMOUNT-1 showed average weight loss of 22.5% at the highest dose over 72 weeks. That's roughly 50% more weight loss than semaglutide in head-to-head comparisons, though individual results vary.

Eli Lilly is offering eligible self-pay patients Zepbound at $449/month for 7.5mg through 15mg dose KwikPens through December 31, 2026. Mounjaro cash-pay pricing is similar.

Liraglutide: Saxenda and Victoza

Saxenda (liraglutide 3mg) was the first GLP-1 approved for weight management. Victoza (liraglutide 1.8mg) is its diabetes-focused counterpart. Both require daily injections — a significant disadvantage compared to the once-weekly newer options.

Clinical trials showed Saxenda produces about 8% body weight loss on average over 56 weeks. That's meaningful but notably less than semaglutide or tirzepatide. Pricing has come down as these drugs age: Saxenda runs about $250-$350/month cash-pay through manufacturer savings programs.

Saxenda still has a role for patients who can't tolerate semaglutide or tirzepatide, or whose insurance covers it preferentially. But for most New York patients in 2026, the newer agents are the first-line choice.

Emerging Options: Retatrutide and Survodutide

Several next-generation GLP-1-based medications are in late-stage clinical trials with potential approval in late 2026 or 2027. Retatrutide (Eli Lilly) is a triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 2 data showed weight loss of up to 24.2% at 48 weeks — and the phase 3 trials are ongoing.

Survodutide (Boehringer Ingelheim / Zealand Pharma) is a dual GLP-1/glucagon agonist showing particular promise for patients with metabolic-associated fatty liver disease (MAFLD). CagriSema (Novo Nordisk), combining semaglutide with cagrilintide, is another pipeline candidate showing strong phase 3 results.

These aren't available yet, but New York patients enrolled in clinical trials at NYU Langone, Mount Sinai, and Weill Cornell can access some of them now.

How Much Do GLP-1 Medications Cost in New York Without Insurance?

Let's talk real numbers. Because the sticker price for GLP-1 drugs remains one of the biggest barriers to access — even in a wealthy city like New York.

Cash-Pay Pricing Breakdown (April 2026)

Medication	Type	Frequency	Cash-Pay Price/Month
Wegovy (injectable)	Semaglutide	Weekly injection	~$349
Ozempic	Semaglutide	Weekly injection	~$349
Oral Wegovy	Semaglutide	Daily pill	$149-$349 (dose-dependent)
Zepbound	Tirzepatide	Weekly injection	~$449
Mounjaro	Tirzepatide	Weekly injection	~$449
Saxenda	Liraglutide	Daily injection	~$250-$350

These prices reflect manufacturer savings programs and direct pricing platforms. Without any discount, list prices remain dramatically higher — Wegovy's list price is over $1,300/month, and Zepbound's exceeds $1,000/month. Nobody should pay list price. If your pharmacy quotes you anything close to that, ask about manufacturer coupons, GoodRx pricing, or switch pharmacies.

The TrumpRx Factor

The White House announced in early 2026 that Ozempic, Wegovy, and Zepbound would be available at roughly $350/month through TrumpRx, a new direct-to-consumer platform. This platform also channels discounts through Medicare and Medicaid. The impact on New York is significant: it essentially caps the cash-pay ceiling for anyone willing to use the program.

Where to Fill Prescriptions in New York

New York City pharmacies vary wildly in GLP-1 pricing and availability. The best bets for consistent stock and competitive pricing:

NovoCare Pharmacy (mail-order): Novo Nordisk's direct pharmacy ships nationwide with manufacturer pricing built in.
Costco Pharmacy (multiple NYC metro locations): Consistently lower markups than chain pharmacies. You don't need a Costco membership to use the pharmacy.
Alto Pharmacy and Capsule (NYC-based delivery pharmacies): Both offer same-day delivery and handle insurance prior authorizations.
Amazon Pharmacy: Competitive cash-pay pricing and Prime member discounts.
GoodRx or RxSaver price comparison: Always check before filling. Prices can differ by $100+ between pharmacies within the same ZIP code.

Supply shortages that plagued New York pharmacies in 2023-2024 have largely resolved. The FDA's drug shortage database removed semaglutide from its shortage list in late 2025, and tirzepatide supply has stabilized as Eli Lilly expanded manufacturing capacity.

Does Insurance Cover GLP-1 Medications in New York?

Insurance coverage is where New York actually has an advantage over many other states. But "advantage" doesn't mean "simple." The coverage landscape is a patchwork that depends on your specific plan, your diagnosis, and sometimes your BMI.

New York State Medicaid

New York is one of 13 states that cover GLP-1 medications for weight loss through Medicaid, with typical copays of $0-$10/month. This is huge. Many states still restrict Medicaid GLP-1 coverage to diabetes indications only. New York's progressive stance means that lower-income residents have access that their counterparts in Texas or Florida don't. For a detailed breakdown of coverage changes across all 50 states, see our state-by-state GLP-1 insurance coverage update.

Eligibility generally requires a BMI of 30+ (or 27+ with a weight-related comorbidity like hypertension, sleep apnea, or type 2 diabetes). Your prescribing physician needs to document medical necessity.

Medicare (Starting July 2026)

This is the biggest coverage expansion of the year. Starting July 2026, Medicare will cover Wegovy and Zepbound at approximately $50/month out-of-pocket for beneficiaries. This follows the inclusion of obesity drugs under Medicare Part D, enabled by the Treat and Reduce Obesity Act provisions and the SELECT trial's cardiovascular benefit data.

For New York's 3.4 million Medicare beneficiaries, this is transformative. Previously, a 67-year-old on Medicare who wanted Wegovy would pay full cash price — $349+ per month. Starting mid-2026, that drops to $50.

Commercial Insurance (Employer Plans)

Coverage varies enormously. Major New York employers with strong GLP-1 coverage include the city and state government employee plans, most major hospital systems (for their own employees), and large financial services firms. JPMorgan Chase, Goldman Sachs, and Citigroup all added or expanded GLP-1 weight management coverage between 2024 and 2025 for their substantial New York workforces.

If your employer plan doesn't cover weight-loss indications, your doctor may be able to get coverage through a diabetes or cardiovascular risk diagnosis. The SELECT trial data — showing that semaglutide reduces major cardiovascular events by 20% — has been a powerful tool for appeals.

New York State Marketplace Plans

Plans purchased through NY State of Health (the ACA marketplace) have variable GLP-1 coverage. Some plans cover them with prior authorization; others exclude weight-loss medications entirely. Check your formulary before enrollment during open enrollment.

Dr. Rekha Kumar, an endocrinologist and obesity medicine specialist previously at Weill Cornell and now in private practice in New York City, notes: "The insurance landscape for GLP-1s is improving faster than most patients realize. I tell every patient to appeal a denial at least once — about 40% of initial denials get overturned on appeal in my experience, especially when we include the cardiovascular data."

Where Can You Get Prescribed GLP-1 Medications in New York City?

Getting a prescription is the first step, and New York offers more pathways than almost any other market in the country. Here's how the options compare.

Academic Medical Centers and Hospital-Based Clinics

For patients with complex medical histories — those with type 2 diabetes, cardiovascular disease, or a BMI over 40 — starting GLP-1 therapy under the supervision of an obesity medicine specialist at an academic center is the gold standard.

Private Obesity Medicine Practices

New York City has seen an explosion of boutique obesity medicine practices since 2023. Many are run by board-certified obesity medicine physicians who left academic centers to offer more personalized care with shorter wait times.

Look for doctors certified by the American Board of Obesity Medicine (ABOM). There are over 400 ABOM-certified physicians in the New York metro area — more than any other metro in the country.

Telehealth Platforms

Telehealth has become the fastest route to a GLP-1 prescription in New York. Most platforms offer consultations within 24-72 hours. The major players operating in New York include:

Ro (Roman): NYC-headquartered. Offers semaglutide and tirzepatide prescriptions through licensed physicians. Medication delivered to your door.
Hims & Hers: Expanded into GLP-1 prescribing in 2024. Competitive pricing on consultations.
Found: Obesity-focused telehealth with ongoing metabolic coaching.
Calibrate: Founded in NYC. Combines GLP-1 prescriptions with a year-long metabolic health program.
Sequence (now WeightWatchers Clinic): Integrates GLP-1 therapy with behavioral coaching.

A word of caution: not all telehealth platforms are equal. Some still prescribe compounded semaglutide despite the FDA ending enforcement discretion for compounded versions when branded supply stabilized. Stick with platforms prescribing FDA-approved brand-name medications from licensed pharmacies.

Primary Care Physicians

Your existing PCP can prescribe GLP-1 medications. Many New York primary care doctors have become comfortable with these prescriptions as the evidence base has grown. If your PCP is hesitant, ask them to refer you to an obesity medicine specialist — or consider a telehealth consultation for the initial prescription while keeping your PCP informed.

What Side Effects Should New York Patients Expect?

Every medication has trade-offs. GLP-1 drugs are effective, but they're not side-effect-free. Understanding what to expect — and when to call your doctor — is critical.

Common Side Effects (Affect 20-50% of Patients)

Nausea is the most reported side effect across all GLP-1 medications. It's most pronounced during dose escalation and typically improves after 4-8 weeks at a stable dose. About 44% of patients in Wegovy clinical trials reported nausea at some point during treatment.

Other GI symptoms include vomiting (24% in trials), diarrhea (30%), constipation (24%), and abdominal pain. These cluster in the first weeks at each new dose level.

Injection site reactions affect about 5-10% of patients using injectable forms — redness, itching, or mild swelling. Rotating injection sites helps.

Serious Side Effects (Rare but Important)

Pancreatitis: Rare but documented. The incidence in clinical trials was about 0.2%. If you develop severe, persistent abdominal pain radiating to the back, seek emergency care.

Gallbladder disease: GLP-1 medications increase the risk of gallstones, particularly with rapid weight loss. About 1-3% of patients develop gallbladder-related complications. New York gastroenterologists report anecdotally that they've seen an uptick in GLP-1-related gallstone cases since 2024.

Thyroid C-cell tumors: GLP-1 medications carry a boxed warning based on animal studies showing thyroid tumors in rodents. This has not been confirmed in humans, but the medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Gastroparesis: Severe delayed gastric emptying has been reported in some patients. Symptoms include persistent nausea, vomiting, and feeling full long after eating. This is uncommon but has received media attention.

Managing Side Effects in Practice

Most New York obesity medicine specialists follow a "start low, go slow" approach to dose escalation. The standard titration schedules can be extended if side effects are significant. Eating smaller meals, avoiding fatty and fried foods, and staying well-hydrated all help with GI symptoms.

For nausea specifically, some doctors prescribe ondansetron (Zofran) during the first few weeks at a new dose. Ginger supplements and peppermint tea are non-pharmaceutical options that patients report helpful.

Protein intake becomes especially important on GLP-1 therapy to preserve lean muscle mass during weight loss. New York nutritionists specializing in GLP-1 patients recommend 1.0-1.2 grams of protein per kilogram of ideal body weight daily. Check out our guide to the best protein powders for GLP-1 users for specific product recommendations.

How Do You Choose Between Semaglutide and Tirzepatide?

This is the question every GLP-1 candidate in New York asks — and there's no universal answer. Both drug classes work. The right choice depends on your specific situation.

Head-to-Head Comparison

No large-scale, randomized head-to-head trial between semaglutide and tirzepatide has been published as of April 2026. We do have indirect comparisons from their respective phase 3 programs:

Factor	Semaglutide (Wegovy/Ozempic)	Tirzepatide (Zepbound/Mounjaro)
Average weight loss	~15% at 68 weeks	~22.5% at 72 weeks
Mechanism	GLP-1 only	Dual GIP/GLP-1
Cardiovascular data	SELECT trial: 20% MACE reduction	CV outcome trial ongoing
Oral option	Yes (approved Dec 2025)	Not yet
Monthly cost (cash)	$149-$349	~$449
Medicare (July 2026)	~$50/month	~$50/month
Nausea rate	~44%	~29-33%

When Semaglutide Might Be Better

You want an oral option and hate needles — oral Wegovy is the only pill GLP-1 approved for weight loss
You have established cardiovascular disease — semaglutide has the SELECT trial data backing cardiovascular benefit
Cost is a primary concern — semaglutide cash-pay starts lower at $149/month (oral) vs. $449 for tirzepatide
Your insurance covers semaglutide but not tirzepatide

When Tirzepatide Might Be Better

You need maximum weight loss — the clinical data consistently shows greater efficacy
You have type 2 diabetes — tirzepatide's dual mechanism shows slightly better A1C reduction
GI side effects concern you — nausea rates are modestly lower with tirzepatide
Your insurance covers tirzepatide (some plans prefer Eli Lilly's products)

The Practical New York Angle

For many New Yorkers, the deciding factor isn't pharmacology — it's access. Which one does your insurance cover? Which one is in stock at your pharmacy? Which one does your doctor have the most experience prescribing?

Start with what your insurance covers. If you're paying cash, semaglutide (especially oral) is more affordable. If maximizing weight loss is the priority and you can manage the cost, tirzepatide's data is compelling.

And remember: you can switch. Many patients start on semaglutide and transition to tirzepatide (or vice versa) if results plateau or side effects are intolerable. Your doctor can guide this decision based on your individual response.

What Role Do GLP-1 Medications Play Beyond Weight Loss?

One of the most fascinating developments in 2025-2026 is the expanding universe of conditions GLP-1 medications may treat. New York research institutions are at the forefront of several of these investigations.

Cardiovascular Protection

The SELECT trial's finding that semaglutide reduces major cardiovascular events by 20% was the single most important data point for GLP-1 adoption in 2024-2025. It shifted the conversation from "weight loss drug" to "cardiometabolic medication" — and that shift unlocked billions in insurance coverage.

Ongoing studies at NYU Langone and Columbia are investigating whether tirzepatide offers similar cardiovascular benefits. Preliminary data from Eli Lilly's SURPASS-CVOT trial is expected later in 2026.

Metabolic-Associated Fatty Liver Disease (MAFLD)

About 30% of American adults have fatty liver disease, and GLP-1 medications show remarkable results in reducing liver fat and inflammation. Semaglutide reduced liver fat by over 50% in some studies. The FDA is reviewing semaglutide for a MAFLD indication.

Addiction and Neurological Applications

Perhaps the most surprising frontier: emerging research suggests GLP-1 medications may reduce addictive behaviors. Studies at Penn Medicine, the University of North Carolina, and other institutions have found associations between GLP-1 use and reduced alcohol consumption, nicotine cravings, and even gambling urges. The mechanism likely involves GLP-1 receptors in the brain's reward pathways. For a deep dive, read our piece on GLP-1 medications and addiction research.

Sleep Apnea

The SURMOUNT-OSA trial showed tirzepatide reduced the severity of obstructive sleep apnea by roughly 50% — as measured by the apnea-hypopnea index — in patients with obesity. This data led to expanded insurance coverage for GLP-1s when prescribed alongside a sleep apnea diagnosis.

Kidney Disease

Semaglutide demonstrated a 24% reduction in chronic kidney disease progression in the FLOW trial. This has significant implications for New York's large diabetic population, many of whom are at risk for diabetic nephropathy.

These expanding indications aren't just scientifically interesting. They have practical implications for New York patients. A GLP-1 medication denied for "weight loss" might be covered when prescribed for cardiovascular risk reduction, fatty liver disease, or sleep apnea. Work with your doctor to identify all applicable diagnoses.

How We Ranked

GLP-1 rankings (medications, providers, comparisons) combine:

Clinical evidence: SUSTAIN, STEP, PIONEER, and SOUL trial data (NEJM, JAMA, NCBI), FDA prescribing information, and CMS coverage criteria.
Patient-reported outcomes: r/Semaglutide, r/Tirzepatide, r/GLP1, and the verified GLP-1 Daily community from the past 12 months. We track patterns in supply shortages, compounding-pharmacy reports, and adverse-event clustering.
First-hand provider testing: editorial telehealth consults to each ranked provider verifying drug source, lab requirements, and continuity of care.

What we never accept: paid placement, compounding-pharmacy referral fees, or sponsorships that influence brand recommendations. Disclosure: affiliate links to vitamin and HSA-related resources appear elsewhere on the site and never affect medication or provider rankings.

Update cadence: each provider quarterly; pricing on demand. Last-updated at top. Email research@theglp1daily.com.

Frequently Asked Questions

Can I get GLP-1 medications through a New York urgent care or walk-in clinic?

Some urgent care chains in New York City have started offering GLP-1 prescriptions, but this isn't ideal for most patients. GLP-1 therapy requires ongoing monitoring — regular check-ins, dose adjustments, lab work, and side effect management. An urgent care visit gives you a one-time prescription without the continuity of care that leads to the best outcomes. Use a PCP, specialist, or telehealth platform that offers follow-up visits instead.

Are compounded GLP-1 medications safe to buy in New York?

Be careful here. Compounded semaglutide and tirzepatide flooded the market during the 2023-2024 shortage. Some compounding pharmacies produce quality products, but the FDA has cracked down on this space as brand-name supply stabilized. In 2026, the safest choice is FDA-approved brand-name medications from licensed pharmacies. If cost is a barrier, manufacturer savings programs, the TrumpRx platform, and insurance coverage expansions make brand-name drugs more affordable than the compounded alternatives were.

How long do I need to take GLP-1 medications?

Current evidence suggests GLP-1 medications work best as long-term therapy. The STEP 1 extension trial showed that patients who stopped semaglutide regained about two-thirds of lost weight within a year. Most obesity medicine specialists in New York treat GLP-1 therapy like blood pressure medication — it manages the condition as long as you take it. Some patients successfully taper to lower maintenance doses, but complete discontinuation usually leads to weight regain.

Do New York health food stores or supplement shops sell GLP-1 alternatives?

You'll find supplements marketed as "natural GLP-1 boosters" at health food stores across the city. Berberine, chromium, and various fiber supplements have been promoted this way. None of them produce weight loss anywhere close to actual GLP-1 medications. Some, like berberine, have modest effects on blood sugar but are not substitutes for pharmaceutical GLP-1 therapy. Don't waste your money expecting comparable results.

Can I fly with GLP-1 injection pens from New York airports?

Yes. TSA allows injectable medications including GLP-1 pens in carry-on luggage. Keep them in their original packaging or pharmacy-labeled container. A travel cooler or insulated case is smart for longer flights since some GLP-1 medications need refrigeration before first use. After first use, most can be stored at room temperature for a limited window (14-28 days depending on the medication). JFK and LaGuardia TSA agents are very familiar with these pens at this point — you won't get hassled.

Sources

CDC National Health Statistics: Obesity prevalence among adults, 2024. cdc.gov
NYC Department of Health and Mental Hygiene, Community Health Survey, 2024.
Jastreboff, A.M., et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine, 2022; 387:205-216. nejm.org
Lincoff, A.M., et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)." New England Journal of Medicine, 2023; 389:2221-2232. nejm.org
IQVIA Institute for Human Data Science, GLP-1 Prescription Trends Report, 2025.
Morgan Stanley Research, "Obesity: The $105 Billion Opportunity," 2025 update.
GoodRx, "Wegovy 2026 Prices, Coupons & Savings Tips," April 2026. goodrx.com
NBC News, "What to watch for in weight loss drugs in 2026," January 2026. nbcnews.com
NPR, "What's ahead for the weight-loss drugs known as GLP-1s in 2026," January 2026. npr.org
GLP Winner, "Medicare GLP-1 Coverage 2026: Just Facts," 2026. glpwinner.com
Packer, M., et al. "Tirzepatide and Obstructive Sleep Apnea (SURMOUNT-OSA)." New England Journal of Medicine, 2024.
Perkovic, V., et al. "Semaglutide and Kidney Outcomes (FLOW Trial)." New England Journal of Medicine, 2024.

-- The GLP-1 Daily Team

Quick Answer